PEG-uricase

Identification

Generic Name
PEG-uricase
DrugBank Accession Number
DB05321
Background

PEG-uricase, a polyethylene glycol ("PEG") conjugate of recombinant porcine uricase (urate oxidase), which breaks down the uric acid deposits is being studied in Phase III clinical trials for the treatment of severe, treatment-refractory gout in the United States in 2006.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
Not Available

Pharmacology

Indication

Investigated for use/treatment in hyperuricemia.

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action

PEG-uricase is a recombinant, PEGylated formulation of a modified porcine urate oxidase intended to dramatically lower the blood level of uric acid safely and continuously in patients who have not benefited from conventional therapeutic approaches. Urate oxidase is a hepatic enzyme present in almost all mammals – but not in humans – that lowers uric acid levels in the blood by converting uric acid into allantoin, a benign substance which is then easily excreted in the urine.

TargetActionsOrganism
UUric acid degradation bifunctional proteinNot AvailableBacillus sp. (strain TB-90)
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Antihemophilic factor (recombinant), PEGylatedThe therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with PEG-uricase.
Certolizumab pegolThe therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with PEG-uricase.
Damoctocog alfa pegolThe therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with PEG-uricase.
ElapegademaseThe therapeutic efficacy of Elapegademase can be decreased when used in combination with PEG-uricase.
LipegfilgrastimThe therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with PEG-uricase.
Methoxy polyethylene glycol-epoetin betaThe therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with PEG-uricase.
Nonacog beta pegolThe therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with PEG-uricase.
PegademaseThe therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegademase.
PegaptanibThe therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegaptanib.
PegaspargaseThe therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegaspargase.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
International/Other Brands
Puricase

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Sherman MR, Saifer MG, Perez-Ruiz F: PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev. 2008 Jan 3;60(1):59-68. Epub 2007 Aug 14. [Article]
  2. Chua CC, Greenberg ML, Viau AT, Nucci M, Brenckman WD Jr, Hershfield MS: Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med. 1988 Jul 15;109(2):114-7. [Article]
PubChem Substance
347910080
Wikipedia
PEG-uricase

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingTreatmentHematopoietic and Lymphoid Cell Neoplasm / Malignant Solid Neoplasm / Tumour lysis syndrome1
3CompletedTreatmentGouty Arthritis1
2CompletedTreatmentGouty Arthritis2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Bacillus sp. (strain TB-90)
Pharmacological action
Unknown
General Function
Urate oxidase activity
Specific Function
Catalyzes two steps in the degradation of uric acid, i.e. the oxidation of uric acid to 5-hydroxyisourate (HIU) and the stereoselective decarboxylation of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazol...
Gene Name
uao
Uniprot ID
Q45697
Uniprot Name
Uric acid degradation bifunctional protein
Molecular Weight
57977.435 Da

Drug created on November 18, 2007 18:23 / Updated on June 12, 2020 16:52